China Resources Shuanghe announced that China Resources Secco, a wholly-owned subsidiary of the company, received the Ezemib atorvastatin calcium tablets and drug registration certificates issued by the State Drug Administration and approved for marketing on September 8, 2026. This certification is considered to have passed the consistency evaluation. The specifications are that each tablet contains 10 mg of ezetimibe and 10 mg of atorvastatin calcium, 10 mg and 20 mg, respectively. As of the announcement date, the total R&D investment was 20.3637 million yuan.

China Resources Shuanghe announced that China Resources Secco, a wholly-owned subsidiary of the company, received the Ezemib atorvastatin calcium tablets and drug registration certificates issued by the State Drug Administration and approved for marketing on September 8, 2026. This certification is considered to have passed the consistency evaluation. The specifications are that each tablet contains 10 mg of ezetimibe and 10 mg of atorvastatin calcium, 10 mg and 20 mg, respectively. As of the announcement date, the total R&D investment was 20.3637 million yuan.